[go: up one dir, main page]

AR037080A1 - Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios - Google Patents

Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios

Info

Publication number
AR037080A1
AR037080A1 ARP010104603A ARP010104603A AR037080A1 AR 037080 A1 AR037080 A1 AR 037080A1 AR P010104603 A ARP010104603 A AR P010104603A AR P010104603 A ARP010104603 A AR P010104603A AR 037080 A1 AR037080 A1 AR 037080A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heteroaryl
group
formula
Prior art date
Application number
ARP010104603A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0023973A external-priority patent/GB0023973D0/en
Priority claimed from GB0107643A external-priority patent/GB0107643D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR037080A1 publication Critical patent/AR037080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)

Abstract

Compuestos de la fórmula (1), en la que: R1 representa alquilo C1-6, alquenilo C2-6, alquinilo C2-6, aril-Y1-, heteroaril-Y1-, aril-(O)t-aril-Y1, aril-(O)t-heteroaril-Y1-, heteroaril-(O)t-aril-Y1-, heteroaril-(O)t-heteroaril-Y1-, aril-SO2-Y1-, (alquil C1-6)-G-Y1-, heteroaril-G-aril-Y1-, J1-SO2-Y1-, R17O(CO)-(alquenil C2-6)-Y1-, R17NHCO-Y1-, R17NHSO2-Y1-, (alquinil C2-6)-Y1-, (alquenil C2-6)-Y1-, aril-O-Y1-, heteroaril-O-Y1-, (alquil C1-6)-SO2-Y1-, M-Y1-, J1-Y1-, J1-CO-Y1-, aril-CO-Y1- ó (cicloalquil C3-8)-Y1- ó (cicloalquenil C3-8)-Y1-; cuyos grupos alquinilo C2-6 y (alquinil C2-6)-Y1 pueden estar opcionalmente sustituidos con un grupo -OR17, cuyo grupo alquenilo C2-6 puede estar opcionalmente sustituido con uno o más grupos -COOR17, y cuyos grupos cicloalquilo o cicloalquenilo pueden estar opcionalmente sustituidos con uno o más grupos hidroxilo o alquilo C1-6; R2 representa hidrógeno o alquilo C1-6 opcionalmente sustituido con un grupo hidroxilo; R3 representa hidrógeno o alquilo C1-6; ó R1 y R2 pueden, conjuntamente con el átomo de nitrógeno al cual están unidos, formar un grupo de la fórmula J2, en donde el átomo de nitrógeno sustituya ya sea a X1 ó X2; t representa 0 ó 1; X representa etileno o un grupo de la fórmula CReRf donde Re y Rf independientemente representan hidrógeno o alquilo C1-4, ó Re y Rf pueden, conjuntamente con el átomo de carbono al cual están unidos, formar un grupo cicloalquilo C3-8; R4 y R5 representan independientemente hidrógeno o alquilo C1-4; Z representa un enlace, CO, SO2, CR10R7(CH2)n, (CH2)nCR10R7, CHR7(CH2)nO, CHR7(CH2)nS, CHR7(CH2)nOCO, CHR7(CH2)nCO, COCHR7(CH2)n ó S2CHR7(CH2)n; R6 representa alquilo C1-6, alquenilo C2-6, aril heteroarilo, aril-(alquenilo C2-6)-, -CN ó un grupo de la fórmula -Y2-J3; R7 representa hidrógeno, alquilo C1-4, CONR8R9 ó COO (alquilo C1-8); a y b representan 1 ó 2, tal que a + b representa 2 ó 3; G representa -SO2-, -SO2NR18, -NR18SO2-, -NR18CO-, CO ó -CONR18-; n representa un número entero de 0 a 4; M representa un grupo cicloalquilo C3-8 ó cicloalquenilo C3-8 fusionado a un grupo arilo monocíclico o heteroarilo monocíclico; J1, J2 y J3 independientemente representan una porción de la fórmula (2) en donde X1 representa oxígeno, NR11 ó azufre, X2 representa CH2, oxígeno, NR12 ó azufre, m1 representa un número entero de 1 a 3 y m2 representa un número entero de 1 a 3; con la condición de que m1 + m2 esté en el intervalo de 3 a 5, también con la condición de que cuando X1 y X2 representen oxígeno, NR11, NR12 o azufre, m1 y m2 deben ambos no ser menor de 2, en donde la fórmula 2 está opcionalmente sustituida con uno o más (por ejemplo 1 ó 2) grupos -Y3-arilo, -Y3-heteroarilo, -Y3-CO-arilo, -CO(cicloalquilo C3-8), -Y3-CO-heteroarilo, -alquilo C1-6, -Y3-COO (alquilo C1-6), -Y3-CO(alquilo C1-6), -Y3-W, -Y3-CO-W-, -Y3-NR15R16, -Y3-CONR15R16, hidroxilo, oxo, -Y3-SO2NR15R16, -Y3-SO2(alquilo C1-6), -Y3-SO2-arilo, -Y3-SO2heteroarilo, -Y3-NR13 (alquilo C1-6), -Y3-NR13SO2 (alquilo C1-6), -Y3-NR13CONR15R16, -Y3-NR13COOR14 ó -Y3-OCONR15R16, y está opcionalmente fusionado a un anillo arilo o heteroarilo monocíclicos; R8, R9, R10, R11, R12, R13 y R14 independientemente representan hidrógeno o alquilo C1-6; R15 y R16 representan independientemente hidrógeno o alquilo C1-6 o R15 y R16 conjuntamente con el átomo de nitrógeno al cual están unidos pueden formar un anillo de morfolina, piperidina o pirrolidina; R17 y R18 independientemente representan hidrógeno ó alquilo C1-6; W representa un anillo saturado o insaturado, no aromático de 5 a 7 miembros, que contiene entre 1 y 3 heteroátomos seleccionados de nitrógeno, oxígeno o azufre; opcionalmente sustituidos con uno o más grupos alquilo C1-6, halógeno o hidroxilo; Y1, Y2 e Y3 representan independientemente un enlace o un grupo de la fórmula -(CH2)pCRcRd(CH2)q- en donde Rc y Rd representan independientemente hidrógeno ó alquilo C1-4, ó Rc y Rd pueden, conjuntamente con el átomo de carbono al cual están unidos, formar un grupo cicloalquilo C3-8 y p y q representan independientemente un número entero de 0 a 5 en donde p + q es un número entero de 0 a 5; con la condición de que el compuesto de la fórmula (1) no sea un compuesto de la fórmula (3), en donde R2' representa hidrógeno o alquilo C1-4; R3' representa hidrógeno; X' representa metileno o etileno; a' y b' ambos representan 1; R4' y R5' ambos representan hidrógeno; y en donde la porción -Z'-R6' representa halobencilo; y las sales y solvatos de los mismos; los procesos para la preparación de los mismos, las composiciones que los contienen, su uso en terapia para el tratamiento de enfermedades inflamatorios, métodos de tratamiento, proceso de preparación e intermediarios.
ARP010104603A 2000-09-29 2001-09-28 Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios AR037080A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0023973A GB0023973D0 (en) 2000-09-29 2000-09-29 Therapeutically useful compounds
GB0107643A GB0107643D0 (en) 2001-03-27 2001-03-27 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
AR037080A1 true AR037080A1 (es) 2004-10-20

Family

ID=26245081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104603A AR037080A1 (es) 2000-09-29 2001-09-28 Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios

Country Status (20)

Country Link
US (1) US7157457B2 (es)
EP (2) EP1586567A1 (es)
JP (1) JP5069392B2 (es)
KR (1) KR20030040510A (es)
CN (1) CN1478084A (es)
AR (1) AR037080A1 (es)
AT (1) ATE345331T1 (es)
AU (1) AU2001290146A1 (es)
BR (1) BR0114321A (es)
CA (1) CA2423305A1 (es)
CZ (1) CZ20031194A3 (es)
DE (1) DE60124576T2 (es)
ES (1) ES2275729T3 (es)
HU (1) HUP0303107A2 (es)
IL (1) IL155092A0 (es)
MX (1) MXPA03002813A (es)
NO (1) NO20031443L (es)
NZ (1) NZ525055A (es)
PL (1) PL362984A1 (es)
WO (1) WO2002026723A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207450D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
ATE416184T1 (de) 2000-08-05 2008-12-15 Glaxo Group Ltd 17.beta.-carbothioat 17.alpha.- arylkarbonyloxyloxy androstanderivate als anti- phlogistische medikamente
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB0207447D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207432D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207436D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207449D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207439D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0211759D0 (en) * 2002-05-22 2002-07-03 Glaxo Group Ltd Novel compounds
GB0212357D0 (en) * 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
EP1486488B1 (en) * 2003-06-10 2009-10-28 Biondi, Ricardo, Miguel Use of a compound of formula I for making a pharmaceutical composition
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
TW200619212A (en) 2004-09-08 2006-06-16 Mitsubishi Pharma Corp Morpholine derivatives
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
TW200837055A (en) * 2007-03-13 2008-09-16 Arete Therapeutics Inc Soluble epoxide hydrolase inhibitors
WO2008123582A1 (ja) 2007-04-04 2008-10-16 Kowa Company, Ltd. テトラヒドロイソキノリン化合物
BRPI0820950A2 (pt) 2007-12-05 2015-07-07 Astrazeneca Ab Composto, formulação farmacêutica, uso de um composto, métodos para o tratamento ou prevenção de condições ou doenças e para inibição da angiogênese, e, processo para a preparação de um composto.
US7851471B2 (en) 2007-12-05 2010-12-14 Astrazeneca Ab (Publ) Compounds I
US20140335083A1 (en) 2011-12-01 2014-11-13 Glaxo Group Limited Methods of treatment and prevention of eye diseases
FR3022142B1 (fr) 2014-06-16 2019-07-12 Universite Paul Sabatier - Toulouse Iii Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate
CN106659717B (zh) 2014-08-22 2019-09-06 葛兰素史密斯克莱知识产权发展有限公司 用于治疗淋病奈瑟球菌感染的三环含氮化合物
EP3570893A1 (en) 2017-01-17 2019-11-27 GlaxoSmithKline Intellectual Property Development Ltd Non peptidic heterobivalent molecules for treating inflammatory diseases
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN111269340B (zh) * 2020-03-31 2020-12-29 台州学院 一种以1-甲烷磺酰哌嗪为配体的螯合树脂及其制备方法和应用
CN120132049B (zh) * 2025-03-05 2025-08-26 西南医科大学附属口腔医院 茶多酚涂层改性的3d打印掺锶羟基磷灰石复合支架的制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
JPH04247074A (ja) * 1991-02-01 1992-09-03 Yoshitomi Pharmaceut Ind Ltd ４−モルホリノ安息香酸誘導体の製造法
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
US5753654A (en) * 1994-05-18 1998-05-19 Nisshin Flour Milling Co., Ltd. Diaminomethylidene derivatives
BR9507892A (pt) 1994-05-18 1997-11-18 Nisshin Flour Milling Co Novos derivados de diamino-metilideno
CA2309332C (en) * 1997-11-12 2002-12-03 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
PL348375A1 (en) 1998-11-20 2002-05-20 Hoffmann La Roche Pyrrolidine derivatives-ccr-3 receptor antagonists
US6441001B1 (en) * 1998-12-18 2002-08-27 Bristol-Myers Squibb Pharma Company 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
CA2346933A1 (en) 1998-12-18 2000-06-22 Dupont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
BR0114321A (pt) 2003-07-01
KR20030040510A (ko) 2003-05-22
JP2004509953A (ja) 2004-04-02
EP1324991A1 (en) 2003-07-09
IL155092A0 (en) 2003-10-31
AU2001290146A1 (en) 2002-04-08
NO20031443D0 (no) 2003-03-28
CZ20031194A3 (cs) 2003-08-13
DE60124576T2 (de) 2007-06-21
PL362984A1 (en) 2004-11-15
ATE345331T1 (de) 2006-12-15
EP1324991B1 (en) 2006-11-15
WO2002026723A1 (en) 2002-04-04
NO20031443L (no) 2003-05-26
CA2423305A1 (en) 2002-04-04
CN1478084A (zh) 2004-02-25
ES2275729T3 (es) 2007-06-16
DE60124576D1 (de) 2006-12-28
EP1586567A1 (en) 2005-10-19
NZ525055A (en) 2004-09-24
MXPA03002813A (es) 2003-10-15
US7157457B2 (en) 2007-01-02
HUP0303107A2 (hu) 2004-03-01
US20040058907A1 (en) 2004-03-25
JP5069392B2 (ja) 2012-11-07

Similar Documents

Publication Publication Date Title
AR037080A1 (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios
AR035205A1 (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
PE20250071A1 (es) Compuesto ciclico que contiene accion inhibidora selectiva en kras por sobre hras y nras
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
AR033845A1 (es) Compuestos de aza y poliaza-naftalenil carboxamidas utiles como inhibidores de la integrasa del vih, composiciones y su uso en la preparacion de medicamentos
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR035617A1 (es) Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios
AR035933A1 (es) Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato.
AR035235A1 (es) Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento
AR059571A1 (es) Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas
AR002012A1 (es) Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
AR043049A1 (es) Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica
CO5560559A2 (es) Formulacion de suspension oral estabilizada
AR034203A1 (es) Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
NO166129C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-9h-pyrido (3,4-b)indoler.
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
ES2059391T3 (es) Derivados de dihidropiridina, su preparacion y su uso.
AR019790A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen. uso para preparar un medicamento
TR200000727T2 (tr) 5HT geri alım inhibitörü ve h5-HT1B antagonistinin bir bileşimi.
AR018159A1 (es) Compuestos derivados de amidin-amino-acidos halogenados utiles como inhibidores de la oxido-nitrico-sintetasa, composicion farmaceutica que los contiene ymetodo de tratamiento
DK1320526T3 (da) Farmaceutisk aktive benzsulfonamidderivater som inhibitorer af protein-junkinaser
RU2001118831A (ru) Макролиды, обладающие противовоспалительной активностью
TR200000725T2 (tr) Bir monoamin oksidaz inhibitörü ve h5-HT1B antagonistinin bileşimi

Legal Events

Date Code Title Description
FA Abandonment or withdrawal